Towards a Unified Model of RAF Inhibitor Resistance

Por Solit, David B., Rosen, Neal
Publicado no Cancer Discov (2014)

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

Por Pratilas, Christine A., Solit, David B.
Publicado em 2010

RAF/MEK dependence of KRAS mutant pancreatic ductal adenocarcinomas

Por Hanrahan, Aphrothiti J., Solit, David B.
Publicado no Cancer Discov (2012)

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

Por Basso, Andrea D, Solit, David B, Munster, Pamela N, Rosen, Neal
Publicado em 2002

(V600E)BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

Por Pratilas, Christine A., Taylor, Barry S., Ye, Qing, Viale, Agnes, Sander, Chris, Solit, David B., Rosen, Neal
Publicado em 2009

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

Por She, Qing-Bai, Solit, David B., Ye, Qing, O’Reilly, Kathryn E., Lobo, Jose, Rosen, Neal
Publicado em 2005

PIK3CA mutation uncouples tumor growth and Cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

Por Halilovic, Ensar, She, Qing-Bai, Ye, Qing, Pagliarini, Raymond, Sellers, William R., Solit, David B., Rosen, Neal
Publicado em 2010

4E-BP1 Is A Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways That Integrates Their Function in Tumors

Por She, Qing-Bai, Halilovic, Ensar, Ye, Qing, Zhen, Wei, Shirasawa, Senji, Sasazuki, Takehiko, Solit, David B., Rosen, Neal
Publicado em 2010

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

Por Sawai, Ayana, Chandarlapaty, Sarat, Greulich, Heidi, Gonen, Mithat, Ye, Qing, Arteaga, Carlos L., Sellers, William, Rosen, Neal, Solit, David B.
Publicado em 2008

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

Por Hyman, David M., Solit, David B., Arcila, Maria E., Cheng, Donavan, Sabbatini, Paul, Baselga, Jose, Berger, Michael F., Ladanyi, Marc
Publicado no Drug Discov Today (2015)

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors

Por de Candia, Paola, Solit, David B., Giri, Dilip, Brogi, Edi, Siegel, Peter M., Olshen, Adam B., Muller, William J., Rosen, Neal, Benezra, Robert
Publicado em 2003

3′-Deoxy-3′-[(18)F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

Por Solit, David B., Santos, Elmer, Pratilas, Christine A., Lobo, Jose, Moroz, Maxim, Cai, Shangde, Blasberg, Ronald, Sebolt-Leopold, Judith, Larson, Steven, Rosen, Neal
Publicado em 2007

MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking

Por Arcila, Maria E., Drilon, Alexander, Sylvester, Brooke E., Lovly, Christine M., Borsu, Laetitia, Reva, Boris, Kris, Mark G., Solit, David B., Ladanyi, Marc
Publicado no Clin Cancer Res (2014)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

Por Chandarlapaty, Sarat, Scaltriti, Maurizio, Angelini, Pierdavide, Ye, Qing, Guzman, Marta, Hudis, Clifford A., Norton, Larry, Solit, David B., Arribas, Joaquin, Baselga, Jose, Rosen, Neal
Publicado em 2009

RAS Mutations Affect Pattern of Metastatic Spread and Increase Propensity for Brain Metastasis in Colorectal Cancer

Por Yaeger, Rona, Cowell, Elizabeth, Chou, Joanne F., Gewirtz, Alexandra N., Borsu, Laetitia, Vakiani, Efsevia, Solit, David B., Rosen, Neal, Capanu, Marinela, Ladanyi, Marc, Kemeny, Nancy
Publicado no Cancer (2014)

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

Por Regales, Lucia, Balak, Marissa N., Gong, Yixuan, Politi, Katerina, Sawai, Ayana, Le, Carl, Koutcher, Jason A., Solit, David B., Rosen, Neal, Zakowski, Maureen F., Pao, William
Publicado em 2007

BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition

Por Yao, Zhan, Torres, Neilawattie M., Tao, Anthony, Gao, Yijun, Luo, Lusong, Li, Qi, de Stanchina, Elisa, Abdel-Wahab, Omar, Solit, David B., Poulikakos, Poulikos, Rosen, Neal
Publicado no Cancer Cell (2015)

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Por Chandarlapaty, Sarat, Sawai, Ayana, Ye, Qing, Scott, Anisa, Silinski, Melanie, Huang, Ken, Fadden, Pat, Partdrige, Jeff, Hall, Steven, Steed, Paul, Norton, Larry, Rosen, Neal, Solit, David B.
Publicado em 2008

3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets

Por Gao, Jianjiong, Chang, Matthew T., Johnsen, Hannah C., Gao, Sizhi Paul, Sylvester, Brooke E., Sumer, Selcuk Onur, Zhang, Hongxin, Solit, David B., Taylor, Barry S., Schultz, Nikolaus, Sander, Chris
Publicado no Genome Med (2017)

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors

Por Aregbe, Abdulateef O., Sherer, Eric A., Egorin, Merrill J., Scher, Howard I., Solit, David B., Ramanathan, Ramesh K., Ramalingam, Suresh, Belani, Chandra P., Ivy, Percy S., Bies, Robert R.
Publicado em 2012